-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: To test the hypothesis that ROSAH (retinal dystrophy, optic edema, splenomegaly, anhidrosis and headache) syndrome caused by dominant mutations in ALPK1 is an autoinflammatory disease
Methods: This cohort study systematically assessed the inflammatory profile of 27 patients with ROSAH syndrome and investigated the impact of ALPK1 mutations on immune signaling
Results: Most of the cohorts carried the p.
Conclusions: ROSAH syndrome is an autoinflammatory disease caused by gain-of-function mutations in ALPK1, and certain features of the disease are suitable for immunomodulatory therapy
Source: Kozycki CT, Kodati S, Huryn L, et al.